Skip to main content
Clinical Trials/EUCTR2006-006088-22-DE
EUCTR2006-006088-22-DE
Active, not recruiting
Phase 1

Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction - Gastripec I

Klinik für Chirurgie, Charité Campus Virchow-Klinikum0 sites180 target enrollmentFebruary 14, 2011

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction
Sponsor
Klinik für Chirurgie, Charité Campus Virchow-Klinikum
Enrollment
180
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 14, 2011
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Klinik für Chirurgie, Charité Campus Virchow-Klinikum

Eligibility Criteria

Inclusion Criteria

  • 1\) patients with gastric cancer incl. adenocarcinoma of the esophagogastreal junction and peritoneal carcinomatosis without any distant metastases with exception of Krukenberger tumosr
  • 2\) peritoneal staging via laparoscopy and assessment of peritoneal carcinomatosis index (PCI) with the possibility of reduction (80% of the tumour) in line with zytoreductive surgery
  • 3\) age \= 18 and \= 75 years
  • 4\) Karnofsky Index \= 70%
  • 5\) written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 180
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • 1\.) distant metastases except peritoneal carcinomatosis and Krukenberg tumors
  • 2\.) other malignoma except curatively treated cervix carcinoma and basal cell carcinoma of the skin
  • 3\.) previous chemotherapy or radiotherapx for peritoneal carcinomatosis
  • 4\.) Inflammation in need of treatment
  • 5\.) NYHA \> 2
  • 6\.) Myocardial infarction
  • 7\.) cardiac arrhythmia
  • 8\.) high blood pressure, constant \> 180/100
  • 9\.) cardiac function EF \< 55%
  • 10\.) Limited heart function

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC)after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junctioMedDRA - 10042080 (stomach cancer)C16D00.2C78.6C79Malignant neoplasm of stomachStomachSecondary malignant neoplasm of retroperitoneum and peritoneumSecondary malignant neoplasm of other and unspecified sites
DRKS00003078Charité Campus Charité Mitte105
Recruiting
Phase 3
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapyC92Myeloid leukaemia
DRKS00023646niversitätsklinikum Freiburg256
Completed
Phase 2
A clinical trial with Sodium Thiosulfate for the treatment of CalciphylaxisCalciphylaxisCirculatory System
ISRCTN73380053Dr. F. Köhler Chemie GmbH (Germany)5
Active, not recruiting
Phase 1
Phase 2/3 Clinical Trial with Sodium Thiosulfate for the Treatment of CalciphylaxisCalciphylaxisMedDRA version: 20.0Level: PTClassification code 10051714Term: CalciphylaxisSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2014-002128-28-ATDr. F. Köhler Chemie GmbH40
Active, not recruiting
Phase 1
Phase 2/3 Clinical Trial with Sodium Thiosulfate for the Treatment of CalciphylaxisCalciphylaxisMedDRA version: 20.0Level: PTClassification code 10051714Term: CalciphylaxisSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2014-002128-28-DEDr. F. Köhler Chemie GmbH40